Neovasc — EuroPCR 2020
11 slides from Neovasc's conference presentation, June 2020
Slide 1: Narrowing of the Coronary Sinus for the Treatment of Refractory Angina Pectoris
Narrowing of the Coronary Sinus for the Treatment of Refractory Angina Pectoris: A multicentre prospective observational open‐label clinical study (REDUCER‐I), Analysis of the first 207 patients
Slide 2: Potential conflicts of interest
Potential conflicts of interest Speaker's name : Stefan Verheye ☑ I have the following potential conflicts of interest to declare: Receipt of honoraria or consultation fees: Biotronik, Elixir Medical, Neovasc Stefan Verheye
Slide 3: Why this study?
Why this study? • Refractory angina is a common disabling condition, which is highly correlated with increased healthcare costs • Patients suffering from refractory angina have poor quality of life but their overall prognosis is similar to that of patients with stable CAD • The coronary sinus (CS) R
Slide 4: What did we study and how was it executed?
What did we study and how was it executed? • Multi-center, international, three-arm prospective and retrospective observational study • Enrollment up to 400 subjects; 241 as of 12 March 2020 • Follow-up through 5 years post implant (Baseline, implant, 30 day, 6 and 12 month, annual) • Primary endpoi
Slide 5: Primary Endpoint: Reduction in CCS Grade
What are the essential results? Primary Endpoint: Reduction in CCS Grade ≥1 Grade ≥2 Grade 100 80/98 81.6% 31/44 126/181 104/140 70.5% 69.6% 74.3% 80 15/44 Patients (%) 60 34.1% 30/98 44/181 36/140 30.6% 40 25.7% 24.3% Stefan 20 Verheye 0 6 Mo 12 Mo 24 Mo 36 Mo Includes data through analysis lock on
Slide 6: What are the essential results?
What are the essential results? with CCS III-IV 70%~ with CCS III-IV 16%~ Stefan Verheye Includes data through analysis lock on 12 March 2020 and is 90% monitored; on file at Neovasc
Slide 7: Why is this important?
Why is this important? 32 MACE reported in 228 subjects that proceeded to the implant procedure • One MI occurring in one subject (0.4%) was adjudicated as procedure and device related Subjects with Subjects with Events Subjects procedure‐ device‐related Event n/N (%) n/N (%) related events events n
Slide 8: What are the essential results?
What are the essential results? COSIRA1 REDUCER‐I2 Change from Change from SAQ Baseline Baseline P‐value Subscale to 6M to 6M N=51 (SD) N= 144 (SD) A change in 9.2 12.23 score of 10 Physical Limitations <0.0001 (20.2) (23.0) points in any of 18.1 15.5 the subscales is Anginal Stability <0.0001 (32.4
Slide 9: What are the essential results?
What are the essential results? Number of Documented Emergency Department Visits Due to Angina in the Past 12Months ED Visits Baseline 12 Months Subjects with at least 1 ED visit in the 41.6% 13.3% last 12 months2 (47/113) (15/113) Sum of ED visits across all subjects 78 22 Average number of ED visi
Slide 10: The essentials to remember
The essentials to remember • REDUCER-I “real-world” data is consistent with the COSIRA randomized double-blind, sham controlled study data • Reducer has a positive clinical effect on patients with refractory angina • A reduction in ED visits by 91.2% • Reducer provides a safe treatment option for pa
Slide 11: PCRonline.com
PCR PCRonline.com